BMRN Earnings Prediction
The chart below shows how BMRN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BMRN sees a +0.89% change in stock price 10 days leading up to the earnings, and a -1.28% change 10 days following the report. On the earnings day itself, the stock moves by -0.02%. This data can give you a slight idea of what to expect for the next quarter's release.
BMRN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
747.31M
15.65%
0.21%
Gross Margin
80.49%
5.49%
8.68%
Operating Margin
22.91%
442.89%
8.53%
Net Margin
16.72%
430.79%
17.58%
EPS
0.64
481.82%
16.36%
No Data Available
BMRN Earnings Analysis
Biomarin Pharmaceutical Inc Corporation (BMRN.O) Earnings Conference Call
Positive
Earnings Beat Expectations: BioMarin Pharmaceutical Inc. exceeded earnings expectations with a reported EPS of $0.64, surpassing the expected $0.54.
Record Growth and Profitability: The company achieved record growth and profitability in 2024, with a year-over-year top line growth of 18%.
Operating Margin Expansion: Non-GAAP operating margin expanded over 900 basis points, reaching 28.6% for the full year 2024.
Earnings Per Share Surge: Non-GAAP diluted earnings per share increased by 69% to $3.52 for the full year 2024, with Q4 EPS rising 88% to $0.92.
Enzyme Therapies Revenue Growth: BioMarin's enzyme therapies business approached $2 billion in annual revenues, growing at 9% year-over-year in Q4 2024.
VOXZOGO Growth Expansion: VOXZOGO for achondroplasia saw a remarkable 56% year-over-year growth, with plans for expansion into hypochondroplasia in 2027.
Projected Revenue Growth: The company anticipates double-digit revenue growth in 2025, projecting total revenues between $3.1 billion and $3.2 billion, representing a 10% increase compared to 2024.
Operating Cash Flow Surge: BioMarin's operating cash flow for 2024 was $573 million, a 260% increase over 2023, supporting long-term revenue growth investments.
Pipeline Advancements in DMD: The strategic prioritization of the pipeline has led to advancements in BMN 351 for Duchenne muscular dystrophy and BMN 333, a long-acting CNP, with expected clinical data results later this year.
Negative
Revenue Growth Deceleration: BioMarin's revenue growth is expected to decelerate in 2025, particularly for NAGLAZYME and ALDURAZYME, due to unique dynamics in 2024 that are not expected to repeat, leading to lower year-over-year growth rates.
R&D Expense Increase: The company anticipates an increase in R&D expenses in 2025 as they ramp up studies for BMN 351, BMN 333, and VOXZOGO indication expansions, which could impact profitability.
Clinical Trial Dependency: There is a reliance on the success of ongoing clinical trials, such as the Phase III study for PALYNZIQ in adolescents, which if unsuccessful, could hinder future growth and market expansion.
Profitability Challenges Ahead: The company is facing challenges with bad debt reserves and higher commercialization expenses for VOXZOGO, which could affect overall profitability.
Future Revenue Challenges: Despite strong performance in 2024, the company acknowledges that achieving their 2025 revenue targets will depend on the successful execution of their growth strategies and the outcomes of their clinical trials.
BMRN FAQs
How does BMRN typically perform around its earnings report dates?
Is Biomarin Pharmaceutical Inc (BMRN) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BMRN Earning Call Sentiment
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q4 2024 Earnings Call Transcript
BMRN.O
2.76%Positive
BioMarin's strong financial performance, including an 18% revenue increase and improved operating margins, coupled with optimistic guidance for 2024 and beyond, suggests a positive outlook. Despite some risks and competitive pressures, the company's robust pipeline, strategic expansion plans, and significant revenue contributions from VOXZOGO support a positive sentiment. The Q&A section highlighted growth opportunities and market expansion, reinforcing the positive sentiment. However, the lack of a shareholder return plan tempers the outlook slightly, preventing a 'Strong positive' rating.
